JP7443230B2 - ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法 - Google Patents

ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法 Download PDF

Info

Publication number
JP7443230B2
JP7443230B2 JP2020524446A JP2020524446A JP7443230B2 JP 7443230 B2 JP7443230 B2 JP 7443230B2 JP 2020524446 A JP2020524446 A JP 2020524446A JP 2020524446 A JP2020524446 A JP 2020524446A JP 7443230 B2 JP7443230 B2 JP 7443230B2
Authority
JP
Japan
Prior art keywords
composition
acid
kda
psa
nanocapsules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020524446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021516211A5 (enExample
JP2021516211A (ja
Inventor
フェルナンデス，マリア ホセ アロンソ
オソリオ，デジレ ティエイロ
ヴァリーノ，カルメン マリア ティエイロ
ピレス，アナ カデテ
Original Assignee
ウニベルシダーデ デ サンティアゴ デ コンポステーラ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシダーデ デ サンティアゴ デ コンポステーラ filed Critical ウニベルシダーデ デ サンティアゴ デ コンポステーラ
Publication of JP2021516211A publication Critical patent/JP2021516211A/ja
Publication of JP2021516211A5 publication Critical patent/JP2021516211A5/ja
Priority to JP2024024604A priority Critical patent/JP7756185B2/ja
Application granted granted Critical
Publication of JP7443230B2 publication Critical patent/JP7443230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2020524446A 2017-11-02 2018-11-02 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法 Active JP7443230B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024024604A JP7756185B2 (ja) 2017-11-02 2024-02-21 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201731277A ES2711669A1 (es) 2017-11-02 2017-11-02 Sistemas de liberacion de farmacos de acido polisialico y metodos
ESP201731277 2017-11-02
PCT/EP2018/080050 WO2019086627A1 (en) 2017-11-02 2018-11-02 Drug delivery systems and methods comprising polysialic acid and/or other polymers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024024604A Division JP7756185B2 (ja) 2017-11-02 2024-02-21 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法

Publications (3)

Publication Number Publication Date
JP2021516211A JP2021516211A (ja) 2021-07-01
JP2021516211A5 JP2021516211A5 (enExample) 2023-11-13
JP7443230B2 true JP7443230B2 (ja) 2024-03-05

Family

ID=64477081

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020524446A Active JP7443230B2 (ja) 2017-11-02 2018-11-02 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
JP2024024604A Active JP7756185B2 (ja) 2017-11-02 2024-02-21 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024024604A Active JP7756185B2 (ja) 2017-11-02 2024-02-21 ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法

Country Status (8)

Country Link
US (1) US20220071917A9 (enExample)
EP (1) EP3703666A1 (enExample)
JP (2) JP7443230B2 (enExample)
AU (1) AU2018361481B2 (enExample)
CA (1) CA3079574A1 (enExample)
ES (1) ES2711669A1 (enExample)
MX (1) MX2020004639A (enExample)
WO (1) WO2019086627A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
AU2020266770A1 (en) 2019-05-01 2021-10-14 Universidade De Santiago De Compostela Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules
EP3986374B1 (en) * 2019-06-21 2026-01-28 Université catholique de Louvain Lipid nanocapsules charged with incretin mimetics
WO2021163097A1 (en) 2020-02-14 2021-08-19 Chang Gung Memorial Hospital Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
CN112048002B (zh) * 2020-08-07 2021-12-10 上海维洱生物医药科技有限公司 一种靶向t细胞的酶敏感纳米体系及其制备方法和应用
CN112402626B (zh) * 2020-11-26 2023-05-02 中国人民解放军陆军军医大学第二附属医院 一种靶向肿瘤的生物伪装纳米递药系统及其制备方法
CA3221371A1 (en) * 2021-06-08 2022-12-15 Cytodigm, Inc. Novel particle composition comprising sialic acid binding ligand
CN115025241B (zh) * 2022-06-22 2023-08-01 西南民族大学 靶向cd22的纳米制剂及其制备方法和应用
WO2024118638A2 (en) * 2022-11-28 2024-06-06 Colorado School Of Mines Compositions and methods for making and using polymer-coated nanocapsules for targeted pharmaceutical agent delivery
WO2025085881A1 (en) 2023-10-20 2025-04-24 Eli Lilly And Company Nanoparticles and formulations thereof for delivering therapeutic agents throughout the central nervous system
EP4652991A1 (en) 2024-05-22 2025-11-26 Universidade de Santiago de Compostela Nanoassemblies for the intracellular delivery of active principles of aminoacidic nature
CN119318719B (zh) * 2024-09-24 2025-09-05 武汉理工大学 一种靶向神经氨酸酶的载药纳米粒及其制备方法和应用
CN119318718B (zh) * 2024-09-24 2025-10-03 武汉理工大学 一种pH/神经氨酸酶双响应载药纳米粒及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516443A (ja) 2008-03-31 2011-05-26 フラウンホーファー・ゲゼルシャフト・ツール・フェルデルング・デア・アンゲヴァンテン・フォルシュング・エー・ファウ 活性薬剤の、肺への標的化送達のためのナノ粒子
US20140023703A1 (en) 2011-01-10 2014-01-23 Universidade De Santiago De Compostela Nanocapsules with a polymer shell
JP2014505695A (ja) 2011-01-24 2014-03-06 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッド 薬物の皮膚及び全身送達のためのナノ粒子
JP2014527980A (ja) 2011-09-21 2014-10-23 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． ナノ送達システム
WO2017014655A1 (en) 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US9993439B2 (en) * 2012-06-20 2018-06-12 University Of Waterloo Mucoadhesive nanoparticle delivery system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516443A (ja) 2008-03-31 2011-05-26 フラウンホーファー・ゲゼルシャフト・ツール・フェルデルング・デア・アンゲヴァンテン・フォルシュング・エー・ファウ 活性薬剤の、肺への標的化送達のためのナノ粒子
US20140023703A1 (en) 2011-01-10 2014-01-23 Universidade De Santiago De Compostela Nanocapsules with a polymer shell
JP2014505695A (ja) 2011-01-24 2014-03-06 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッド 薬物の皮膚及び全身送達のためのナノ粒子
JP2014527980A (ja) 2011-09-21 2014-10-23 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． ナノ送達システム
WO2017014655A1 (en) 2015-07-17 2017-01-26 Uniwersytet Jagiellonski Nanocapsule for delivery of lipophilic compound and process of preparation thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biomacromolecules，2011年，12，314-320
International Journal of Pharmaceutics，2010年，385，150-156

Also Published As

Publication number Publication date
MX2020004639A (es) 2020-11-06
US20210228494A1 (en) 2021-07-29
EP3703666A1 (en) 2020-09-09
AU2018361481B2 (en) 2024-06-13
JP2024059777A (ja) 2024-05-01
WO2019086627A1 (en) 2019-05-09
CA3079574A1 (en) 2019-05-29
ES2711669A1 (es) 2019-05-06
US20220071917A9 (en) 2022-03-10
JP2021516211A (ja) 2021-07-01
JP7756185B2 (ja) 2025-10-17
AU2018361481A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP7756185B2 (ja) ポリシアル酸および／またはその他のポリマーを含む薬物送達のシステムおよび方法
Wu et al. Milk-derived exosomes exhibit versatile effects for improved oral drug delivery
Koren et al. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity
Li et al. Regulation of protein corona on liposomes using albumin-binding peptide for targeted tumor therapy
Stavnsbjerg et al. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists
JP6214004B2 (ja) ナノ送達システム
EP3897742A2 (en) Antibody drug conjugates (adc) containing saponin
EP2623097B1 (en) Solid lipid nanoparticles including elastin-like polypeptides and use thereof
Logie et al. Preclinical evaluation of taxane-binding peptide-modified polymeric micelles loaded with docetaxel in an orthotopic breast cancer mouse model
Eltoukhy et al. Nucleic acid-mediated intracellular protein delivery by lipid-like nanoparticles
AU2458501A (en) Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
Yang et al. Bioresponsive chimaeric nanopolymersomes enable targeted and efficacious protein therapy for human lung cancers in vivo
EP3962491B1 (en) Intracellular delivery of anti-kras antibodies formulated into nanocapsules
US20190167589A1 (en) Biomimetic proteolipid vesicle compositions and uses thereof
Wang et al. One-step self-assembling method to prepare dual-functional transferrin nanoparticles for antitumor drug delivery
EP3678706A1 (en) Albumin-modified nanoparticles carrying a targeting ligand
Wöll et al. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells
Zhang et al. PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: An alternative to PEGylation
Sasaki et al. Alpha-dystroglycan binding peptide A2G80-modified stealth liposomes as a muscle-targeting carrier for Duchenne muscular dystrophy
Jabbari Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles
Subasic et al. Dose-dependent production of anti-PEG IgM after intramuscular PEGylated-hydrogenated soy phosphatidylcholine liposomes, but not lipid nanoparticle formulations of DNA, correlates with the plasma clearance of PEGylated liposomal doxorubicin in rats
Varghese et al. Potential nanocarriers for the delivery of drugs to the brain
US20250352664A1 (en) Meth0ds of administering lipid nanoparticles including poly(ethyloxazoline)-lipid conjugates without raising immune response to polymer
Martins et al. Intelligent delivery of antitumor drugs mediated by polymeric nanomicelles: a review
WO2025254653A1 (en) Peptide-targeted layer-by-layer nanoparticle for glioblastoma treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230929

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240221

R150 Certificate of patent or registration of utility model

Ref document number: 7443230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150